Literature DB >> 29524043

Chemokine CXCL3 mediates prostate cancer cells proliferation, migration and gene expression changes in an autocrine/paracrine fashion.

Hua Xin1, Yu Cao1, Ming-Liang Shao2, Wei Zhang2, Chun-Bin Zhang3, Jing-Tao Wang3, Li-Chun Liang3, Wen-Wu Shao3, Ya-Ling Qi4, Yue Li3, Ze-Yu Zhang1, Zhe Yang1, Yu-Hong Sun1, Peng-Xia Zhang3, Lin-Lin Jia5, Wei-Qun Wang6.   

Abstract

INTRODUCTION: We have previously indicated that CXCL3 was upregulated in the tissues of prostate cancer, and exogenous administration of CXCL3 played a predominant role in the tumorigenicity of prostate cancer cells. In the present study, we further explored the role and the underlying mechanism of CXCL3 overexpression in the oncogenic potential of prostate cancer in an autocrine/paracrine fashion.
METHODS: CXCL3-overexpressing prostate cancer cell line PC-3 and immortalized prostate stromal cell line WPMY-1 were established by gene transfection. CCK-8, transwell assays and growth of tumor xenografts were conducted to characterize the effects of CXCL3 on PC-3 cells' proliferation and migration. Western blotting was conducted to test whether CXCL3 could affect the expression of tumorigenesis-associated genes.
RESULTS: The results showed that CXCL3 overexpression in PC-3 cells and the PC-3 cells treated with the supernatants of CXCL3-transfected WPMY-1 cells stimulated the proliferation and migration of PC-3 cells in vitro and in a nude mouse xenograft model. Western blotting revealed higher levels of p-ERK, Akt and Bcl-2 and lower levels of Bax in the tumor xenografts transplanted with CXCL3-transfected PC-3 cells. Moreover, the tumor xenografts derived from the PC-3 cells treated with supernatants of CXCL3-transfected WPMY-1 cells showed higher expression of ERK, Akt and Bcl-2 and lower expression of Bax.
CONCLUSIONS: These findings suggest that CXCL3 autocrine/paracrine pathways are involved in the development of prostate cancer by regulating the expression of the target genes that are related to the progression of malignancies.

Entities:  

Keywords:  Autocrine; CXCL3; Chemokines; Paracrine; Prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 29524043     DOI: 10.1007/s11255-018-1818-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  26 in total

1.  Overexpression of CXCL3 can enhance the oncogenic potential of prostate cancer.

Authors:  Shi-Liang Gui; Li-Chen Teng; Shu-Qiu Wang; Shuang Liu; Ying-Li Lin; Xiao-Lian Zhao; Lei Liu; Hong-Yu Sui; Yang Yang; Li-Chun Liang; Mo-Lin Wang; Xin-Yi Li; Yu Cao; Feng-Ying Li; Wei-Qun Wang
Journal:  Int Urol Nephrol       Date:  2016-02-02       Impact factor: 2.370

Review 2.  CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

Authors:  G Elizabeth Pluhar; Christopher A Pennell; Michael R Olin
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

3.  Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation.

Authors:  Satoko Matsumura; Sandra Demaria
Journal:  Radiat Res       Date:  2010-04       Impact factor: 2.841

4.  MicroRNA-21 promotes the proliferation and inhibits apoptosis in Eca109 via activating ERK1/2/MAPK pathway.

Authors:  Fengxia Liu; Shutao Zheng; Tao Liu; Qing Liu; Meng Liang; Xiuling Li; Ilyar Sheyhidin; Xiaomei Lu; Wenya Liu
Journal:  Mol Cell Biochem       Date:  2013-05-25       Impact factor: 3.396

5.  IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells.

Authors:  Romaine I Fernando; Marianne D Castillo; Mary Litzinger; Duane H Hamilton; Claudia Palena
Journal:  Cancer Res       Date:  2011-06-08       Impact factor: 12.701

6.  PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.

Authors:  Natasa Obermajer; Ravikumar Muthuswamy; Kunle Odunsi; Robert P Edwards; Pawel Kalinski
Journal:  Cancer Res       Date:  2011-10-24       Impact factor: 12.701

7.  Expression and gene polymorphisms of the chemokine CXCL5 in colorectal cancer patients.

Authors:  Jan Dimberg; Olaf Dienus; Sture Löfgren; Anders Hugander; Dick Wågsäter
Journal:  Int J Oncol       Date:  2007-07       Impact factor: 5.650

8.  Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.

Authors:  Pamela J Maxwell; Jessica Neisen; Johanna Messenger; David J J Waugh
Journal:  Oncotarget       Date:  2014-07-15

9.  CXCL3 contributes to CD133(+) CSCs maintenance and forms a positive feedback regulation loop with CD133 in HCC via Erk1/2 phosphorylation.

Authors:  Lin Zhang; Lixing Zhang; Hong Li; Chao Ge; Fangyu Zhao; Hua Tian; Taoyang Chen; Guoping Jiang; Haiyang Xie; Ying Cui; Ming Yao; Jinjun Li
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

10.  Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.

Authors:  Jitian Li; Liping Dai; Ningjing Lei; Mengtao Xing; Pei Li; Chenglin Luo; Carlos A Casiano; Jian-Ying Zhang
Journal:  Oncotarget       Date:  2016-07-12
View more
  10 in total

1.  RNA-seq and Network Analysis Reveal Unique Chemokine Activity Signatures in the Synovial Tissue of Patients With Rheumatoid Arthritis.

Authors:  Runrun Zhang; Yehua Jin; Cen Chang; Lingxia Xu; Yanqin Bian; Yu Shen; Yang Sun; Songtao Sun; Steven J Schrodi; Shicheng Guo; Dongyi He
Journal:  Front Med (Lausanne)       Date:  2022-05-04

2.  Plasma CXCL3 Levels Are Associated with Tumor Progression and an Unfavorable Colorectal Cancer Prognosis.

Authors:  Can Cui; Rui Zhang; Feng Gu; Yunfeng Pei; Li Sun; Yueyang Huang; Guoping Niu; Jian Li
Journal:  J Immunol Res       Date:  2022-05-26       Impact factor: 4.493

3.  Prediction and identification of immune genes related to the prognosis of patients with colon adenocarcinoma and its mechanisms.

Authors:  Sihan Chen; G D Cao; Wu Wei; Lu Yida; He Xiaobo; Yang Lei; Chen Ke; Bo Chen; Mao Ming Xiong
Journal:  World J Surg Oncol       Date:  2020-06-29       Impact factor: 2.754

Review 4.  Tumor progression locus 2 (TPL2) in tumor-promoting Inflammation, Tumorigenesis and Tumor Immunity.

Authors:  Lucy Wanjiru Njunge; Andreanne Poppy Estania; Yao Guo; Wanqian Liu; Li Yang
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

5.  Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion.

Authors:  Ne Guo; Meng-Zhu Li; Li-Min Wang; Hua-Dong Chen; Shan-Shan Song; Ze-Hong Miao; Jin-Xue He
Journal:  Cancer Biol Ther       Date:  2022-01-09       Impact factor: 4.742

6.  In Prostate Cancer Cells Cytokines Are Early Responders to Gravitational Changes Occurring in Parabolic Flights.

Authors:  Herbert Schulz; Dorothea Dietrichs; Markus Wehland; Thomas J Corydon; Ruth Hemmersbach; Christian Liemersdorf; Daniela Melnik; Norbert Hübner; Kathrin Saar; Manfred Infanger; Daniela Grimm
Journal:  Int J Mol Sci       Date:  2022-07-17       Impact factor: 6.208

7.  Hub Genes and Key Pathway Identification in Colorectal Cancer Based on Bioinformatic Analysis.

Authors:  Jian Lv; Lili Li
Journal:  Biomed Res Int       Date:  2019-11-06       Impact factor: 3.411

8.  Construction of a CXC Chemokine-Based Prediction Model for the Prognosis of Colon Cancer.

Authors:  Kaisheng Liu; Minshan Lai; Shaoxiang Wang; Kai Zheng; Shouxia Xie; Xiao Wang
Journal:  Biomed Res Int       Date:  2020-03-30       Impact factor: 3.411

9.  Integrative Bioinformatics Analysis Reveals Potential Target Genes and TNFα Signaling Inhibition by Brazilin in Metastatic Breast Cancer Cells.

Authors:  Adam Hermawan; Herwandhani Putri
Journal:  Asian Pac J Cancer Prev       Date:  2020-09-01

10.  MicroRNA-506 has a suppressive effect on the tumorigenesis of nonsmall-cell lung cancer by regulating tubby-like protein 3.

Authors:  Zhan-Hua Li; Ji-Hong Zhou; Si-Ning Chen; Ling Pan; Yuan Feng; Mei-Qun Luo; Rui-Xiang Li; Gui-Li Sun
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.